JP2008537673A5 - - Google Patents

Download PDF

Info

Publication number
JP2008537673A5
JP2008537673A5 JP2007553371A JP2007553371A JP2008537673A5 JP 2008537673 A5 JP2008537673 A5 JP 2008537673A5 JP 2007553371 A JP2007553371 A JP 2007553371A JP 2007553371 A JP2007553371 A JP 2007553371A JP 2008537673 A5 JP2008537673 A5 JP 2008537673A5
Authority
JP
Japan
Prior art keywords
antibody
ephb2
seq
hvr
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007553371A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008537673A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/003502 external-priority patent/WO2006083936A2/en
Publication of JP2008537673A publication Critical patent/JP2008537673A/ja
Publication of JP2008537673A5 publication Critical patent/JP2008537673A5/ja
Pending legal-status Critical Current

Links

JP2007553371A 2005-01-31 2006-01-31 抗ephb2抗体とその使用方法 Pending JP2008537673A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64854105P 2005-01-31 2005-01-31
US75684406P 2006-01-05 2006-01-05
PCT/US2006/003502 WO2006083936A2 (en) 2005-01-31 2006-01-31 Anti-ephb2 antibodies and methods using same

Publications (2)

Publication Number Publication Date
JP2008537673A JP2008537673A (ja) 2008-09-25
JP2008537673A5 true JP2008537673A5 (enExample) 2009-02-26

Family

ID=36341431

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007553371A Pending JP2008537673A (ja) 2005-01-31 2006-01-31 抗ephb2抗体とその使用方法

Country Status (7)

Country Link
US (2) US7767205B2 (enExample)
EP (1) EP1844076A2 (enExample)
JP (1) JP2008537673A (enExample)
AU (1) AU2006210837B2 (enExample)
CA (1) CA2594636A1 (enExample)
NZ (1) NZ556317A (enExample)
WO (1) WO2006083936A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2802205C (en) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
NZ583292A (en) 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
AU2005332660A1 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
EP1833996B1 (en) * 2005-01-06 2012-12-05 Genentech, Inc. Cancer prognostic methods
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
AU2006269422B2 (en) 2005-07-07 2012-12-06 Seagen Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
US20100297140A1 (en) 2006-08-31 2010-11-25 A.C.N 135 493 391 Pty Ltd As Trustee For Conca Unit Trust Uses of antibodies
RU2557319C2 (ru) 2007-07-16 2015-07-20 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ
MY150531A (en) 2007-07-16 2014-01-30 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
DK2657253T3 (en) 2008-01-31 2017-10-09 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
EA201290192A1 (ru) 2009-11-07 2013-02-28 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EP2849797B1 (en) 2012-05-15 2019-12-18 Concortis Biosystems, Corp Drug-conjugates, conjugation methods, and uses thereof
WO2015057876A1 (en) 2013-10-15 2015-04-23 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
BR112016007622A2 (pt) 2013-10-15 2018-01-23 Seattle Genetics, Inc. composto, composição farmacêutica, conjugado de ligante-droga, e, método para tratar câncer
CN106536551B (zh) * 2014-02-06 2021-04-16 X4制药(奥地利)有限责任公司 大肠杆菌特异性抗体序列
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
EP3250238B1 (en) 2015-01-28 2022-06-01 Sorrento Therapeutics, Inc. Antibody drug conjugates
WO2017089606A1 (en) * 2015-11-26 2017-06-01 Kotter Mark Reinhard Therapy to increase remyelination
SG11201804268RA (en) 2015-12-04 2018-06-28 Seattle Genetics Inc Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
BR112018069273A2 (pt) 2016-03-25 2019-01-22 Seattle Genetics Inc métodos para preparação de um composto e para tratamento de um indivíduo com uma malignidade hematológica, composto, composição, e, intermediário ligante de fármaco ou composto ligante de fármaco
US11046782B2 (en) 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
US11730822B2 (en) 2017-03-24 2023-08-22 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
AU2002232405A1 (en) * 2000-11-20 2002-05-27 California Institute Of Technology Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor
CA2633595A1 (en) * 2001-06-20 2003-01-03 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
AU2003291736A1 (en) * 2002-11-05 2004-06-03 Cell Signaling Technology, Inc. Methods and materials for examining pathways associated with glioblastoma progression
NZ583292A (en) * 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
EP1740954B1 (en) * 2004-04-07 2015-08-19 Genentech, Inc. Mass spectrometry of antibody conjugates
EP1833996B1 (en) * 2005-01-06 2012-12-05 Genentech, Inc. Cancer prognostic methods

Similar Documents

Publication Publication Date Title
JP2008537673A5 (enExample)
JP2008546780A5 (enExample)
RU2423382C1 (ru) Композиции и способы диагностики и лечения опухоли
JP2014509835A5 (enExample)
CN103517719B (zh) 抗体-药物缀合物
JP2013056896A5 (enExample)
US10052382B2 (en) Methods for using antibodies for 3′ iso-LM1 and 3′, 6′-iso-LD1tumor gangliosides
HK1214161A1 (zh) 抗IL-13受体α2抗体和抗体-药物缀合物
JP2008529497A5 (enExample)
JP2018534933A5 (enExample)
JP2006507013A5 (enExample)
IL290591B2 (en) Antibody drug preparations (ADC) that bind to 191P4D12 proteins
JP2014520088A5 (enExample)
JP2017522861A5 (enExample)
JP2014524902A5 (enExample)
RU2007133108A (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ
JP2018509146A (ja) Flt3タンパク質に結合する抗体薬物複合体(adc)
JP2014531201A5 (enExample)
RU2015142815A (ru) Лечение рака с использованием антител, связывающихся с поверхностным grp78
JP2020522280A5 (enExample)
JP2019205480A5 (enExample)
JP2020522281A5 (enExample)
RU2016118573A (ru) Анти-ly6e антитела и способы применения
RU2012127351A (ru) Композиции и способы для диагностики и лечения опухоли
JP2024016024A5 (enExample)